However, another study which recruited 42 Ashkenazi Jewish women who were FANCC heterozygous carriers showed that the risk of breast cancer was not significantly elevated in the carriers (both 2.2% for the carriers and controls) (25). This evidence concerns the gene FANCC and breast carcinoma.